[Skip to Content]
[Skip to Content Landing]
February 25, 2004

Magnesium Sulfate for Preterm Neuroprotection—Reply

Author Affiliations

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(8):940-941. doi:10.1001/jama.291.8.941-a

In Reply: In response to Dr Ananth and colleagues, the primary purpose of reporting the combined outcome of death or substantial gross motor dysfunction is because the 2 components represent competing risks—a child cannot have motor dysfunction at 2 years if he or she has already died. Because we had found a significantly reduced number of survivors with gross motor dysfunction (reduced from 6.6% to 3.4%) it was important to establish that this was not achieved through an excess of deaths in the magnesium group.

First Page Preview View Large
First page PDF preview
First page PDF preview